不整脈の考え方、治し方

出版社： 中外医学社
著者：
発行日： 2019-08-01
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784498136564
電子書籍版： 2019-08-01 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,720 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,720 円(税込)

購入する

商品紹介

著しい進歩ゆえ治療選択が複雑化した不整脈．常に最適な治療戦略を行ううえで，必須の基本的知識から，検査，治療法を確定するに至るそもそもの考えかたなどを，各エキスパートが解説した．研修医や不整脈を苦手とする若手医師にも理解しやすいよう，専門的過ぎる内容はあえて除き，現場で使える実践的な知識を凝縮している．また，最新の不整脈非薬物療法ガイドラインも反映させ，必読の不整脈解説本となっている．

目次

  • Ch. 1　不整脈の見かた
    　1　不整脈患者の症状と病歴・身体所見の見かた
    　2　不整脈患者の症状と検査の見かた
    　3　不整脈の発生機序
    　4　遺伝性不整脈の見かた
    　5　EPS検査の概要（装置，刺激法など）について
    　6　エントレインメントの見かた
    　7　Para‒Hisian pacing update
    　8　上室頻拍の鑑別診断に役立つ電気生理現象の見かた
    　9　研修医からの質問―不整脈の何がわからない？

    Ch. 2　　不整脈治療の考えかた
    　1　徐脈性不整脈
    　2　頻脈性不整脈

    Ch. 3　　不整脈治療の実践
    　1　救急室で必要な不整脈治療マニュアル
    　2　研修医に是非知ってほしい不整脈治療のコツ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Ch.1 不整脈の見かた

P.10 掲載の参考文献
1) The Task Force for the diagnosis and management of syncope of the European Society of Cardiology (ESC). 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018 ; 39 : 1883-948.
 
2) Sheldon R. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol. 2002 ; 40 : 142-8.
PubMed
3) Wishwa NK. Primary care : syncope. N Engl J Med. 2000 ; 343 : 1856-62.
 
4) John S. Convulsive syncope induced by ventricular arrhythmia masquerading as epileptic seizures : case report and literature review. J Clin Med Res. 2016 ; 8 : 610-5.
 
5) Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 1 : Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med. 1997 ; 126 : 989-96.
PubMed
6) 循環器病の診断と治療に関するガイドライン (2011年年度合同研究班報告). 失神の診断・治療ガイドライン (2012年改訂版).
 
7) Ralston SH, Penman ID, Strachan MWJ, et al. Davidson's principles and practice of medicine. 23rd ed. Elsevier ; 2018.
 
8) Lloyd AR. Syncope : evaluation and differential diagnosis. Am Fam Physician. 2017 ; 95 : 303-12B.
 
9) Grossman SA. Do outcomes of near syncope parallel syncope? Am J Emerg Med. 2012 ; 30 : 203-6.
PubMed
10) Weber BE, Kapoor WN. Evaluation and outcomes of patients with palpitations. Am J Med. 1996 ; 100 : 138-48.
PubMed
11) Martin Dolgin. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. The Criteria Committee of the New York Heart Association ; 1994.
 
12) 吉川純一. 循環器フィジカル・イグザミネーションの実際. 東京 : 文光堂 ; 2005.
 
13) Ejaz AA. Orthostatic hypotension : characteristics of 100 consecutive patients presenting with orthostatic hypotension. Mayo Clin Proc. 2004 ; 79 : 890-4.
PubMed
14) Mathieu P, Mathieu C, Etienne P, et al. Carotid sinus massage. N Engl J Med. 2017 ; 377 : e21.
 
15) 羽田勝征. 新心エコーの読み方, 考え方. 改訂4版. 東京 : 中外医学社 ; 2018.
 
16) 坂本二哉. 心エコーハンドブック 心臓聴診エッセンシャルズ. 京都 : 金芳堂 ; 2012.
 
P.18 掲載の参考文献
1) 池田隆徳, 編. 不整脈の症状と身体所見. ステップアップのための不整脈診療ガイドブック. 東京 : メジカルビュー社 ; 2011. p.37-42.
 
2) Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 ; 370 : 2467-77.
PubMed
3) 失神の診断・治療ガイドライン (2012年改訂版). 日本循環器学会ガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2012_inoue_h.pdf
 
4) Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 ; 370 : 2478-86.
PubMed
P.24 掲載の参考文献
1) 高橋尚彦. 不整脈の基盤となる病態. In : 池田隆徳, 編. 不整脈診療Skill Upマニュアル. 東京 : 羊土社 ; 2008. p.19-22.
 
2) 高橋尚彦. 頻拍の機序. In : 土谷健, 高橋尚彦. 不整脈プロフェッショナル. 東京 : 南江堂, 2010. p.43-8.
 
3) 高橋尚彦. 不整脈. In : 犀川哲典, 小野克重, 編. シンプル循環器. 東京 : 南江堂 ; 2015. p.269-304.
 
P.37 掲載の参考文献
1) Antzelevitch C, Yan GX. J-wave syndromes : Brugada and early repolarization syndromes. Heart Rhythm. 2015 ; 12 : 1852-66.
PubMed
2) Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome : consensus report. Circulation. 2002 ; 106 : 2514-9.
PubMed
3) Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 ; 10 : 1932-54.
PubMed
4) Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995 ; 91 : 1512-9.
PubMed
5) Sumitomo N. Current topics in catecholaminergic polymorphic ventricular tachycardia. J Arrhythm. 2016 ; 32 : 344-51.
PubMed
6) Laitinen PJ, Brown KM, Pippo K, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001 ; 103 : 485-90.
 
7) Lahat H, Elder M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine-or exercise-induced polymorphic ventricular tachycardia : clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation. 2001 ; 103 : 2822-7.
PubMed
8) Vega AL, Tester DJ, Ackerman MJ, et al. Protein kinase A-dependent biophysical phenotype for V227F-KCNJ2 mutation in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2009 ; 2 : 540-7.
PubMed
9) Nyegaard M, Overgaard MT, Sondergaard MT, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet. 2012 ; 91 : 703-12.
PubMed
10) Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet. 2012 ; 21 : 2759-67.
PubMed
11) Zhou Q, Xiao J, Jiang D, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2＋release. Nat Med. 2011 ; 17 : 1003-9.
 
12) Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009 ; 15 : 380-3.
PubMed
13) van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011 ; 57 : 2244-54.
PubMed
14) Hwang HS, Hasdemir C, Laver D, et al. Inhibition of cardiac Ca2＋release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2011 ; 4 : 128-35.
 
15) Coleman MA, Bos JM, Johnson JN, et al. Videoscopic left cardiac sympathetic denervation for patients with recurrent ventricular fibrillation/malignant ventricular arrhythmia syndromes besides congenital long-QT syndrome. Circ Arrhythm Electrophysiol. 2012 ; 5 : 782-8.
PubMed
16) Kaneshiro T, Naruse Y, Nogami A, et al. Successful catheter ablation of bidirectional ventricular premature contractions triggering ventricular fibrillation in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation. Circ Arrhythm Electrophysiol. 2012 ; 5 : e14-7.
PubMed
17) Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome : proposed diagnostic criteria. J Am Coll Cardiol. 2011 ; 57 : 802-12.
PubMed
18) Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004 ; 109 : 30-5.
PubMed
19) Sumitomo N. E1784K mutation in SCN5A and overlap syndrome. Circ J. 2014 ; 78 : 1839-40.
PubMed
20) Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008 ; 358 : 2016-23.
PubMed
P.47 掲載の参考文献
1) Josephson ME. Clinical cardiac electrophysiology. Techniques and interpretation. 2nd ed. Lea & Febiger ; 1993. p.22-70.
 
2) 井上博, 奥村謙, 他. EPS臨床心臓電気生理検査. 第2版. 東京 : 医学書院 ; 2007. p.9-85.
 
3) 小川聡, 他. 臨床心臓電気生理検査に関するガイドライン (2011改訂版) : 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告).
 
4) 循環器病の診断と治療に関するガイドライン (2010-2011年度合同研究班報告). カテーテルアブレーションの適応と手技に関するガイドライン.
 
5) Veenhuyen G, Quinn R, Wilton S, et al. Diagnostic pacing maneuvers for supraventricular tachycardia : Part 1. PACE. 2011 ; 34 : 767-82.
 
6) Hirao K, Otomo K, Wang X, et al. Para-Hisian pacing. A new method for differentiating retrograde conduction over an accessory AV pathway from conduction over the AV node. Circulation. 1996 ; 94 : 1027-35.
PubMed
7) Maruyama M, Kobayashi Y, Miyauti Y, et al. The VA relationship after differential atrial overdrive pacing : a novel tool for the diagnosis of atrial tachycardia in the electrophysiologic laboratory. J Cardiovasc Electrophysiol. 2007 ; 18 : 1127-33.
 
8) Nishizaki M, Sakurada H, Ohta T, et al. Factors for transient entrainment of ventricular tachycardia by rapid atrial pacing. Am J Cardiol. 1993 ; 71 : 699-704.
PubMed
9) Knight BP, Zivin A, Souza J, et al. A technique for the rapid diagnosis of atrial tachycardia in the electrophysiology laboratory. J Am Coll Cardiol. 1999 ; 33 : 775-81.
 
10) Gonzalez-Torrecilla E, Arenal A, Atienza F, et al. First postpacing interval after tachycardia entrainment with correction for atrioventricular node delay : a simple maneuver for differential diagnosis of atrioventricular nodal reentrant tachycardias versus orthodromic reciprocating tachycardias. Heart Rhythm. 2006 ; 6 : 674-79.
 
11) Segal OR, Gula LJ, Skanes AC, et al. Differential ventricular entrainment : maneuver to differentiate AV node reentrant tachycardia from orthodromic reciprocating tachycardia. Heart Rhythm. 2009 ; 6 : 493-500.
 
12) Nagashima K, Kumar S, Stevenson WG, et al. Anterograde conduction to the His bundle during right ventricular overdrive pacing distinguishes septal pathway atrioventricular reentry from atypical atrioventricular nodal reentrant tachycardia. Heart Rhythm. 2015 ; 12 : 735-43.
 
13) Stevenson WG, Khan H, Sager P, et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation. 1993 ; 88 : 1647-70.
PubMed
P.52 掲載の参考文献
1) Okumura K, Henthorn RW, Epstein AE, et al. Further observations on transient entrainment. Importance of pacing site and properties of the components of the reentry circuit. Circulation. 1985 ; 72 : 1293-307.
PubMed
2) Okumura K, Olshansky B, Henthorn RW, et al. Demonstration of the presence of slow conduction during sustained ventricular tachycardia in man. Use of transient entrainment of the tachycardia. Circulation. 1987 ; 75 : 369-78.
PubMed
3) Henthorn RW, Okumura K, Olshansky B, et al. A fourth criterion for transient entrainment. The electrogram equivalent of progressive fusion. Circulation. 1988 ; 77 : 1003-12.
PubMed
4) Stevenson WG, Friedman PL, Sager PT, et al. Exploring postinfarction reentrant ventricular tachycardia with entrainment mapping. J Am Coll Cardiol. 1997 ; 29 : 1180-9.
PubMed
5) Okumura K, Okamatsu H. Entrainment pacing : a diagnostic tool for reentrant tachycardia and its application for catheter ablation. In : Hirao K, ed. Catheter ablation. https://doi.org/10.1007/978-981-10-4463-2_3, Springer Nature Singapore Pte Ltd. 2018
 
P.59 掲載の参考文献
1) Hirao K, Otomo K, Wang X, et al. Para-Hisian pacing. A new method for differentiating retrograde conduction over an accessory AV pathway from conduction over the AV node. Circulation. 1996 ; 94 : 1027-35.
PubMed
2) Obeyesekere M, Leong-Sit P, Skanes A, et al. Determination of inadvertent atrial capture during para-Hisian pacing. Circ Arrhythm Electrophysiol. 2011 ; 4 : 510-4.
PubMed
P.68 掲載の参考文献
1) Bennett MT, Leong-Sit P, Gula LJ, et al. Entrainment for distinguishing atypical atrioventricular node reentrant tachycardia from atrioventricular reentrant tachycardia over septal accessory pathways with long-RP [corrected] tachycardia. Circ Arrhythm Electrophysiol. 2011 ; 4 : 506-9.
 
2) AlMahameed ST, Buxton AE, Michaud GF. New criteria during right ventricular pacing to determine the mechanism of supraventricular tachycardia. Circ Arrhythm Electrophysiol. 2010 ; 3 : 578-84.
PubMed
3) Knight BP, Zivin A, Souza J, et al. A technique for the rapid diagnosis of atrial tachycardia in the electrophysiology laboratory. J Am Coll Cardiol. 1999 ; 33 : 775-81.
 
4) Kaneko Y, Naito S, Okishige K, et al. Atypical fast-slow atrioventricular nodal reentrant tachycardia incorporating a "superior"slow pathway : a distinct supraventricular tachyarrhythmia. Circulation. 2016 ; 133 : 114-23.
PubMed
5) Kaneko Y, Nakajima T, Irie T, et al. Atrial and ventricular activation sequence after ventricular induction/entrainment pacing during fast-slow atrioventricular nodal reentrant tachycardia : new insight into the use of V-A-A-V for the differential diagnosis of supraventricular tachycardia. Heart Rhythm. 2017 ; 14 : 1615-22.
 
6) Maruyama M, Kobayashi Y, Miyauchi Y, et al. The VA relationship after differential atrial overdrive pacing : a novel tool for the diagnosis of atrial tachycardia in the electrophysiologic laboratory. J Cardiovasc Electrophysiol. 2007 ; 18 : 1127-33.
PubMed
7) Stavrakis S, Jackman WM, Lockwood D, et al. Slow/fast atrioventricular nodal reentrant tachycardia using the inferolateral left atrial slow pathway. Circ Arrhythm Electrophysiol. 2018 ; 11 : e006631.
PubMed
8) Kaneko Y, Nakajima T, Nogami A, et al. Atypical fast-slow atrioventricular nodal reentrant tachycardia utilizing a slow pathway extending to the inferolateral right atrium. Circ Rep. 2019 ; 1 : 46-54.
 
9) Kaneko Y, Nakajima T, Iizuka T, et al. A case of atypical fast-slow atrioventricular nodal reentrant tachycardia utilizing a slow pathway extending to the superoanterior right atrium. Int Heart J. in press.
 
10) Yamabe H, Okumura K, Morihisa K, et al. Demonstration of anatomical reentrant tachycardia circuit in verapamil-sensitive atrial tachycardia originating from the vicinity of the atrioventricular node. Heart Rhythm. 2012 ; 9 : 1475-83.
PubMed
11) Padanilam BJ, Manfredi JA, Steinberg LA, et al. Differentiating junctional tachycardia and atrioventricular node re-entry tachycardia based on response to atrial extrastimulus pacing. J Am Coll Cardiol. 2008 ; 52 : 1711-7.
PubMed
P.86 掲載の参考文献
1) Sheldon R, Killam S. Methodology of isoproterenol-tilt table testing in patients with syncope. J Am Coll Cardiol. 1992 ; 19 : 773-9.
 
2) Brignole M, Deharo JC, De Roy L, et al. Syncope due to idiopathic paroxysmal atrioventricular block : long-term follow-up of a distinct form of atrioventricular block. J Am Coll Cardiol. 2011 ; 58 : 167-73.
PubMed
3) Toivonen L, Kadish A, Kou W, et al. Determinants of the ventricular rate during atrial fibrillation. J Am Coll Cardiol. 1990 ; 16 : 1194-200.
PubMed
4) Kato T, Yamashita T, Sagara K, et al. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. Circ J. 2004 ; 68 : 568-72.
PubMed
5) Wijffels MC, Kirchhof Cj, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995 ; 92 : 1954-68.
PubMed
6) Mizusawa Y, Sakurada H, Nishizaki M, et al. Characteristics of bundle branch reentrant ventricular tachycardia with a right bundle branch block configuration : feasibility of atrial pacing. Europace. 2009 ; 11 : 1208-13.
PubMed
7) Merino JL, Peinado R, Fernandez-Lozano I, et al. Bundle-branch reentry and the postpacing interval after entrainment by right ventricular apex stimulation : a new approach to elucidate the mechanism of wide-QRS-complex tachycardia with atrioventricular dissociation. Circulation. 2001 ; 103 : 1102-8.
PubMed
8) Neiger JS, Trohman RG. Differential diagnosis of tachycardia with a typical left bundle branch block morphology. World J Cardiol. 2011 ; 3 : 127-34.
PubMed
9) Priori SG, Wilde Aa, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 ; 10 : 1932-63.
PubMed
10) Benito B, Guasch E, Rivard L, et al. Clinical and mechanistic issues in early repolarization of normal variants and lethal arrhythmia syndromes. J Am Coll Cardiol. 2010 ; 56 : 1177-86.
PubMed
11) Baher AA, Uy M, Xie F, et al. Bidirectional ventricular tachycardia : ping pong in the His-Purkinje system. Heart Rhythm. 2011 ; 8 : 599-605.
PubMed
12) Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994 ; 89 : 206-15.
PubMed
13) Haissaguerre M, Shah DC, Jais P, et al. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet. 2002 ; 359 : 677-8.
PubMed
14) Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002 ; 106 : 962-7.
PubMed
P.97 掲載の参考文献
1) Al-Khatib SM, Arshad A, Balk EM, et al. Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation : a systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2016 ; 13 : e222-37.
 
2) Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation. 1994 ; 90 : 1262-78.
PubMed
3) Peters RW, Shorofsky SR, Pelini M, et al. Overdrive atrial pacing for conversion of atrial flutter : comparison of postoperative with non-postoperative patients. Am Heart J. 1999 ; 137 : 100-3.
 
4) Yoshizawa R, Kojima K, Komatsu T. Radiofrequency catheter ablation for inappropriate sinus tachycardia in a patient with systemic lupus erythematosus : a case report. Eur Heart J. 2019 ; 40 (22) : in press.
 
5) 日本循環器学会. 循環器病の診断と治療に関するガイドライン 2009. 不整脈薬物治療に関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
6) Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guideline for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 ; 37 : 2893-962.
PubMed
7) CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol StudyII (CIBIS-II) : a randomized trial. Lancet. 1999 ; 353 : 9-13.
 
8) Roth A, Elkayam I, Shapira I, et al. Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular tachyarrhythmias causing unstable hemodynamicstates. Am J Cardiol. 2003 ; 91 : 489-91.
PubMed
9) Mehta D, Wafa S, Ward DE, et al. Relative efficacy of various physical maneuvers in the termination of junctional tachycardia. Lancet. 1988 ; 1 : 1181-5.
PubMed
10) Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999 ; 99 : 1034-40.
PubMed
11) Furlong R, Gerhardt RT, Farber P, et al. Intravenous adenosine as first-line prehospital management of narrow-complex tachycardias by EMS personnel without direct physician control. Am J Emerg Med. 1995 ; 13 : 383-8.
PubMed
12) Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction. -comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study) -. Circ J. 2013 ; 77 : 908-16.
 
13) Ogawa S, Yamashita T, Yamazaki T, et al. J-RHYTHM Investigators. Optimal treatment strategy for patients with paroxysmal atrial fibrillation : J-RHYTHM Study. Circ J. 2009 ; 73 : 242-8.
PubMed
14) Brooks AG, Stiles MK, Laborderie JL, et al. Outcome of long-standing persistent atrial fibrillation : a systematic review. Heart Rhythm. 2010 ; 7 : 835-46.
 
15) Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death : Data from Swedish health registries. Eur Heart J. 2016 ; 37 : 2478-87.
PubMed
16) Fauchier L, Samson A, Chaize G, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012 : a nationwide database study. Open Heart. 2015 ; 2 : e000290. doi : 10.1136.
 

Ch.2 不整脈治療の考えかた

P.104 掲載の参考文献
1) ACLSプロバイダーマニュアルAHAガイドライン 2015. 東京 : シナジー ; 2017.
 
P.113 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf
 
2) Mulpuru SK, Madhavan M, McLeod CJ, et al. Cardiac pacemakers : function, troubleshooting, and management : part 1 of a 2-part series. J Am Coll Cardiol. 2017 ; 69 : 189-210.
 
3) Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. In Press, Accepted Manuscript, Available online 6 November 2018.
 
4) Josephson ME. Josephson's clinical cardiac electrophysiology : techniques and interpretations. 5th ed. Wolters Kluwer ; 2015. p.93-112.
 
5) Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013 ; 61 : e6-75.
 
6) Rubenstein JJ, Schulman CL, Yurchak PM, et al. Clinical spectrum of the sick sinus syndrome. Circulation. 1972 ; 46 : 5-13.
PubMed
7) European Society of Cardiology (ESC) ; European Heart Rhythm Association (EHRA) ; Brignole M, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy : the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013 ; 15 : 1070-118.
 
8) S・セルジュ・バロルド, ローランド・X・ストローハンド. 著. 庄田守男, 他訳. イラストで学ぶ心臓ペースメーカーStep by step. 東京 : 医学書院 ; 2017. p.317-9.
 
9) Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med. 2007 ; 357 : 1000-8.
PubMed
P.117 掲載の参考文献
1) Udo EO, Zuithoff NPA, Van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy : The FOLLOWPACE study. Hear Rhythm. 2012 ; 9 : 728-35.
 
2) Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations : An analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014 ; 35 : 1186-94.
PubMed
3) Reynolds D, Duray GZ, Omar R, et al. A leadless intracardiac transcatheter pacing system. N Engl J Med. 2016 ; 374 : 533-41.
 
4) Roberts PR, Clementy N, Al Samadi F, et al. A leadless pacemaker in the real-world setting : The Micra Transcatheter Pacing System Post-Approval Registry. Hear Rhythm. 2017 ; 14 : 1375-9.
 
5) Soejima K, Asano T, Ishikawa T, et al. Performance of Leadless Pacemaker in Japanese Patients vs. Rest of the World-Results From a Global Clinical Trial-. Circ J. 2017 ; 81 : 1589-95.
PubMed
6) Chinitz L, Ritter P, Khelae SK, et al. Accelerometer-based atrioventricular synchronous pacing with a ventricular leadless pacemaker : results from the Micra atrioventricular feasibility studies. Hear Rhythm. 2018 ; 15 : 1363-71.
 
P.124 掲載の参考文献
1) Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart : the scientific foundations of cardiac repair. J Clin Invest. 2005 ; 115 : 572-83.
PubMed
2) Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009 ; 104 : e30-41.
PubMed
3) Yoshida A, Lee JK, Tomoyama S, et al. In vitro platform of allogeneic stem cell-derived cardiomyocyte transplantation for cardiac conduction defects. Europace. 2018 ; 20 : 1553-60.
PubMed
4) Takahashi T, Nagai T, Kanda M, et al. Regeneration of the cardiac conduction system by adipose tissue-derived stem cells. Circ J. 2015 ; 79 : 2703-12.
PubMed
5) Kapoor N, Liang W, Marban E, et al. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat Biotechnol. 2013 ; 31 : 54-62.
PubMed
6) Protze SI, Liu J, Nussinovitch U, et al. Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker. Nat Biotechnol. 2017 ; 35 : 56-68.
PubMed
P.129 掲載の参考文献
1) Evans R, Shaw DB. Pathological studies in sinoatrial disorder (sick sinus syndrome). Br Heart J. 1977 ; 39 : 778-86.
PubMed
2) Thery C, Grosselin B, Lekieffre J, et al. Pathology of sinoatrial node. Correlation with electrocardiographic findings. Am Heart J. 1977 ; 93 : 735-40.
 
3) Sugiura M, Ohkawa S. A clinicopathologic study on sick sinus syndrome with histological approach to the sinoatrial node. Jpn Circ J. 1980 ; 44 : 497-504.
 
4) Josephson ME. Sinus node function. In : Clinical cardiac electrophysiology, techniques and interpretations. 2nd ed. Pennsylvania : Lea & Febliger ; 1993. p.71-95.
 
5) 八木洋, 鈴木秀夫, 杉野敬一, 他. 洞自動能, 洞房伝導能に対するoverdrive suppressionの臨床的意義と自律神経系のoverdrive suppressionに及ぼす影響 ; 洞結節電位直接記録法による検討. 心電図. 1996 ; 16 : 360-8.
 
6) 戸叶隆司, 中田八洲郎, 佐々木玲聡, 他. 洞機能不全症候群における右心房不応期のdispersionに関する検討. 心電図. 2004 ; 24 : 49-58.
Medical*Online
7) Rubenstein JJ, Schulman CL, Yurchak PM, et al. Clinical spectrum of the sick sinus syndrome. Circulation. 1972 ; 46 : 5-13.
PubMed
8) Hayashi K, Fukunaga M, Yamaji K, et al. Impact of catheter ablation for paroxysmal atrial fibrillation in patients with sick sinus syndrome. Circ J. 2016 ; 80 : 887-94.
PubMed
9) Kim D-H, Choi J-II, Lee KN, et al. Long-term outcomes of catheter ablation in patients with atrial fibrillation predisposing to tachycardia-bradycardia syndrome : a long pause predicts implantation of a permanent pacemaker. BMC Cardiovascular Disorders. 2018 ; 18 : 106-13.
 
10) Hocini M, Sanders P, Deisenhofer I, et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation. 2003 ; 108 : 1172-5.
PubMed
11) Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017 ; 14 : e275-444.
PubMed
12) Khaykin Y, Marrouche NF, Martin DO, et al. Pulmonary vein isolation for atrial fibrillation in patients with symptomatic sinus bradycardia or pauses. J Cardiovasc Electrophysiol. 2004 ; 15 : 784-9.
PubMed
13) Miyanaga S, Yamane T, Date T, et al. Impact of pulmonary vein isolation on the autonomic modulation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses. Europace. 2009 ; 11 : 576-81.
PubMed
14) Inada K, Yamane T, Tokutake K, et al. The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pause : outcome during a 5-year follow-up. Europace. 2014 ; 16 : 208-13.
PubMed
15) Chen Y-W, Bai R, Lin T, et al. Pacing or ablation : Which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome? PACE. 2014 ; 37 : 403-11.
PubMed
16) Hada M, Miyazaki S, Kajiyama T, et al. Catheter ablation pf paroxysmal atrial fibrillation in patients with sick sinus syndrome. Heart and Vessels. 2018 ; 34 : 503-8.
 
P.136 掲載の参考文献
1) Hocini M, Sanders P, Deisenhofer I, et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation. 2003 ; 108 : 1172-5.
PubMed
2) Inada K, Yamane T, Tokutake K, et al. The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses : outcome during 5-year follow-up. Europace. 2014 ; 16 : 208-13.
PubMed
3) Hayashi K, Fukunaga M, Yamaji K, et al. Impact of catheter ablation for paroxysmal atrial fibrillation in patients with sick sinus syndrome-important role of non-pulmonary vein foci-. Circ J. 2016 ; 80 : 887-94.
PubMed
4) Masuda M, Inoue K, Iwakura K, et al. Preprocedural ventricular rate predicts subsequent sick sinus syndrome after ablation for long-standing persistent atrial fibrillation. PACE. 2012 ; 35 : 1074-80.
PubMed
5) Kawaji T, Shizuta S, Yamagami S, et al. Impact of pre-existing bradycardia on subsequent need for pacemaker implantation after radiofrequency catheter ablation for atrial fibrillation. Circ J. 2018 ; 82 : 2493-9.
PubMed
6) Kim DH, Choi J, No Lee K, et al. Long-term clinical outcomes of catheter ablation in patients with atrial fibrillation predisposing to tachycardia-bradycardia syndrome : a long pause predicts implantation of a permanent pacemaker. BMC Cardiovasc Disord. 2018 ; 18 : 106.
 
7) Akoum N, Mcgann C, Vergara G, et al. Atrial fibrosis quantified using late gadolinium enhancement MRI is associated with sinus node dysfunction requiring pacemaker implant. J Cardiovasc electrophysiol. 2012 ; 23 : 44-50.
PubMed
8) Chen YW, Bai R, Lin T, et al. Pacing or Ablation : Which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome? PACE. 2014 ; 37 : 403-11.
PubMed
P.148 掲載の参考文献
1) Delaney B, Loy J, Kelly AM. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults : a meta-analysis. Eur J Emerg Med. 2011 ; 18 : 148-52.
PubMed
2) Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 ; 37 : 2893-962.
PubMed
3) Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010 ; 362 : 1363-73.
PubMed
4) Chao TF, Liu CJ, Tuan TC, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015 ; 132 : 1604-12.
PubMed
5) Kotecha D, Holmes J, Krum H, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet. 2014 ; 384 : 2235-43.
 
6) Nielsen PB, Larsen TB, Gorst-Rasmussen A, et al. β-blockers in atrial fibrillation patients with or without heart failure : association with mortality in a nationwide cohort study. Circ Heart Fail. 2016 ; 9 : e002597.
 
7) Vadmann H, Nielsen PB, Hjortshoj SP, et al. Atrial flutter and thromboembolic risk : a systematic review. Heart. 2015 ; 101 : 1446-55.
 
8) Yamabe H, Tanaka Y, Morihisa K, et al. Electrophysiologic mechanism of typical atrial flutter termination by nifekalant : effect of a pure IKr-selective blocking agent. Pacing Clin Electrophysiol. 2013 ; 36 : 1123-31.
PubMed
9) Sihm I, Hansen FA, Rasmussen J, et al. Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. Eur Heart J. 1990 ; 11 : 145-8.
PubMed
10) Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial : I. Report on arrhythmia and other findings. J Am Coll Cardiol. 1984 ; 4 : 1148-63.
 
11) Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000 ; 21 : 2071-8.
PubMed
12) Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 ; 352 : 225-37.
 
P.169 掲載の参考文献
1) Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992 ; 85 (1 Suppl) : I2-10.
 
2) Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017 ; 72 : e91-220.
 
3) Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 ; 37 : 2129-200.
 
4) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf (2019/4閲覧)
 
5) Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 ; 352 : 225-37.
 
6) Shiga T, Hagiwara N, Ogawa H, et al ; Heart Institute of Japan Acute Myocardial Infarction-II (HIJAMI-II) Investigators. Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era : results from the HIJAMI-II registry. Heart. 2009 ; 95 : 216-20.
PubMed
7) Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of adefibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 ; 346 : 877-83.
PubMed
8) Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007 ; 298 : 405-12.
PubMed
9) 遺伝性不整脈の診療に関するガイドライン (2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_aonuma_h.pdf (2018/6/16参照)
 
P.175 掲載の参考文献
1) Lewis GF, Gold MR. Safety and efficacy of the subcutaneous implantable defibrillator. J Am Coll Cardiol. 2016 ; 67 : 445-54.
PubMed
2) Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator. J Am Coll Cardiol. 2015 ; 65 : 1605-15.
PubMed
3) Bardy GH, Smith WM, Grace AA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010 ; 363 : 36-44.
PubMed
4) Basu-Ray I, Liu J, Jia X, et al. Subcutaneous versus transvenous implantable defibrillator therapy. A meta-analysis of case-control studies. J Am Coll Cardiol. 2017 ; 26 : 1475-83.
 
5) Sholevar DP, Tung S, Kuriachan V, et al. Feasibility of extravascular pacing with a novel substernal electrode configuration : The Substernal Pacing Acute Clinical Evaluation study. Heart Rhythm. 2018 ; 15 : 536-42.
PubMed
6) Tjong FVY, Brouwer TF, Koop B, et al. Acute and 3-month performance of a communicating leadless antitachycardia pacemaker and subcutnaous implantable defibrillator. JACC Clin Electrophysiol. 2017 ; 3 : 1487-98.
PubMed
P.181 掲載の参考文献
1) 相澤義房, 他. 心臓突然死の予知と予防法のガイドライン. Cir J. 2005 ; 69 Suppl : 1253.
 
2) AVID investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997 ; 337 : 1576.
 
3) Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013 ; 127 : e283.
 
4) Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992 ; 85 (1 Suppl) : I2-10.
 
5) Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996 ; 335 : 1933.
 
6) Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 ; 346 : 877.
PubMed
7) Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999 ; 341 : 1882.
 
8) Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 ; 352 : 225.
 
9) 日本循環器学会/日本不整脈心電学会ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版). www.j-circ.or.jp/guideline/JCS2018_kurita_nogami.pdf
 
10) Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005 ; 352 : 2581.
 
11) Hohnloser SH, Kuek KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004 ; 351 : 2481.
 
12) Steinbeck G, Andresen D, Seidi K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009 ; 361 : 1427.
 
13) Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014 ; 11 : e166.
PubMed
14) Klein HU, Goldenberg I, Moss AJ. Risk stratification for implantable cardioverter defibrillator therapy : the role of the wearable cardioverter-defibrillator. Eur Heart J. 2013 ; 34 : 2230.
PubMed
15) 庭野慎一, 他. 着用型自動除細動器 (WCD) の臨床使用に関するステートメント (2018年2月改訂). http://new.jhrs.or.jp/pdf/guideline/statement
 
16) Niwano S, Sekiguchi Y, Ishii Y, et al. Clinical Usefulness of Wearable Cardioverter Defibrillator (WCD) and Current Understanding of Its Clinical Indication in Japan. Circ J. 2018 ; 82 : 1481.
PubMed
17) Sasaki S, Tomita H, Shibutani S, et al Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circ J. 2014 ; 78 : 2987.
PubMed
18) Kishihara J, Niwano S, Nakamura H, et al. An appropriate shock of the wearable cardioverter defibrillator in outpatient setting. J Arrhythmia. 2016 ; 32 : 67.
 
19) Kutyifa V, Moss AJ, Klein H, et al Use of the wearable cardioverter defibrillator in high-risk cardiac patients : data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation. 2015 ; 132 : 1613.
PubMed
20) Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012 ; 367 : 2275-83.
PubMed
21) Olgin JE, Pletcher MJ, Vittinghoff E, et al. Werable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018 ; 379 : 1205-15.
 
P.186 掲載の参考文献
1) Shimizu A, Nitta T, Kurita T, et al. Actual conditions of implantable defibrillation therapy over 5 years in Japan. J Arrhythmia. 2012 ; 28 : 263-72.
 
2) Huang DT, Sesselberg HW, McNitt S, et al. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function : a MADIT-II substudy. J Cardiovasc Electrophysiol. 2007 ; 18 : 833-8.
PubMed
3) Al-Khatib SM, Hellkamp, Bardy GH, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013 ; 309 : 55-62.
PubMed
4) Pokorney SD, Miller AL, Chen AT, et al. Implantable cardioverter-defibrillator use among medicare patients with low ejection fraction after acute myocardial infarction. JAMA. 2015 ; 313 : 2433-40.
 
5) Chen CY, Stevenson LW, Stewart GC, et al. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admission for exacerbation of heart failure or other acute co-morbidities : cohort study of older patients with heart failure. BMJ. 2015 ; 351 : h3529.
PubMed
P.190 掲載の参考文献
1) Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy : a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2013 ; 61 : 1318-68.
 
2) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版). www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf
 
3) Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillatoramong elderly patients with a history of life threatening ventricular arrhythmias. Eur Heart J. 2007 ; 28 : 1746-9.
PubMed
4) Krahn AD, Connolly SJ, Roberts RS, et al ; ATMA Investigators. Diminishing proportional risk of sudden death with advancing age : implications for prevention of sudden death. Am Heart J. 2004 ; 147 : 837-40.
PubMed
5) Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 ; 352 : 225-37.
 
6) Santangeli P, Di Biase L, Dello RA, et al. Meta-analysis : age and effectiveness of prophylactic implantable cardioverter defibrillators. Ann Intern Med. 2010 ; 153 : 592-9.
 
7) Mezu U, Adelstein E, Jain S, et al. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death. Am J Cardiol. 2011 ; 108 : 718-22.
PubMed
8) Boriani G, Ricci R, Toselli T, et al. Implantable cardioverter defibrillators : from evidence of trials to clinical practice. Eur Heart J Suppl. 2007 ; 9 : 166-73.
 
9) Goonewardene M, Barra S, Heck P, et al. Cardioverter-defibrillator implantation and generator replacement in the octogenarian. Europace. 2015 ; 17 : 409-16.
PubMed
10) Koplan BA, Epstein LM, Albert CM, et al. Survival in octogenarians receiving implantable defibrillators. Am Heart J. 2006 ; 152 : 714-9.
PubMed
11) Kini V, Soufi MK, Deo R, et al. Appropriateness of primary prevention implantable cardioverter defibrillators at time of generator replacement : are indications still met? J Am Coll Cardiol. 2014 ; 63 : 2388-94.
 
12) Kramer DB, Buxton AE, Zimetbaum PJ. Time for a change-a new approach to ICD replacement. N Engl J Med. 2012 ; 366 : 291-3.
 
13) Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 2012 ; 59 : 2075-9.
 
14) Tsai V, Goldstein MK, Hsia HH, et al. National Cardiovascular Data's ICD Registry. Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States. Circ Cardiovasc Qual Outcomes. 2011 ; 4 : 549-56.
 
15) Krahn AD, Lee DS, Birnie D, et al. Predictors of short-term complications after implantable cardioverter-defibrillator replacement : results from the Ontario ICD Database. Circ Arrhythm Electrophysiol. 2011 ; 4 : 136-42.
PubMed
16) Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures : results from the REPLACE registry. Circulation. 2010 ; 122 : 1553-61.
 
17) Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000 ; 21 : 2071-8.
PubMed
18) Barra S, Providencia R, Paiva L, et al. Implantable cardioverter-defibrillators in the elderly : rationale and specific age-related considerations. Europace. 2015 ; 17 : 174-86.
PubMed
P.202 掲載の参考文献
1) Yokoyama K, Nakagawa H, Shah DC, et al. Novel contact force sensor incorporated in irrigated radiofrequency ablation catheter predicts lesion size and incidence of steam pop and thrombus. Circ Arrhythm Electrophysiol. 2008 ; 1 : 354-62.
PubMed
2) Nakagawa H, Kautzner J, Natale A, et al. Locations of high contact force during left atrial mapping in atrial fibrillation patients : electrogram amplitude and impedance are poor predictors of electrode-tissue contact force for ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2013 ; 6 : 746-53.
PubMed
3) Neuzil P, Reddy VY, Kautzner J, et al. Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment : results from the EFFICAS I study. Circ Arrhythm Electrophysiol. 2013 ; 6 : 327-33.
PubMed
4) Reddy VY, Shah D, Kautzner J, et al. The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm. 2012 ; 9 : 1789-95.
PubMed
5) Perna F, Heist EK, Danik SB, et al. Assessment of catheter tip contact force resulting in cardiac perforation in swine atria using force sensing technology. Circ Arrhythm Electrophysiol. 2011 ; 4 : 218-24.
PubMed
6) Kimura M, Sasaki S, Owada S, et al. Comparison of lesion formation between contact force-guided and non-guided circumferential pulmonary vein isolation : a prospective, randomized study. Heart Rhythm. 2014 ; 11 : 984-91.
PubMed
7) Sohns C, Karim R, Harrison J, et al. Quantitative magnetic resonance imaging analysis of the relationship between contact force and left atrial scar formation after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2014 ; 25 : 138-45.
PubMed
8) Matsumoto K, Okumura K, Kobayashi Y, et al. safety and efficacy of cryoballoon for the treatment of paroxysmal AF in Japan : results from the multicenter Japanese prospective post-market surveillance study. "The CRYO-Japan PMS Study". Circ J. 2016 ; 25 : 1744-9.
 
9) Kuck KH, Brugada J, Furnkranz A, et al. for the FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. New Engl J Med. 2016 ; 374 : 2235-45.
 
10) Dukkipati SR, Cuoco F, Kutinsky I, et al. Pulmonary vein isolation using the visually guided laser balloon : a prospective, multicenter, and randomized comparison to standard radiofrequency ablation. J Am Coll Cardiol. 2015 ; 66 : 1350-60.
 
P.208 掲載の参考文献
1) Sosa E, Scanavacca M, d'Avila A, et al. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Electrophysiol. 1996 : 7 ; 531-6.
 
2) Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol. 2010 ; 55 : 2366-72.
PubMed
3) Berte B, Sacher F, Cochet H, et al. Postmyocarditis ventricular tachycardia in patients with epicardial-only scar : a specific entity requiring a specific approach. J Cardiovasc Electrophysiol. 2015 ; 26 : 42-50.
PubMed
4) Dukkipati SR, d'Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2011 ; 4 : 185-94.
PubMed
5) Yoshiga Y, Mathew S, Wissner E, et al. Correlation between substrate location and ablation strategy in patients with ventricular tachycardia late after myocardial infarction. Heart Rhythm. 2012 ; 9 : 1192-9.
PubMed
6) Bazan V, Gerstenfeld EP, Garcia FC, et al. Site-specific twelve-lead ECG features to identify an epicardial origin for left ventricular tachycardia in the absence of myocardial infarction. Heart Rhythm. 2007 ; 4 : 1403-10.
PubMed
7) Bazan V, Bala R, Garcia FC, et al. Twelve-lead ECG features to identify ventricular tachycardia arising from the epicardial right ventricle. Heart Rhythm. 2006 ; 3 : 1132-9.
PubMed
8) Martinek M, Stevenson WG, Inada K, et al. QRS characteristics fail to reliably identify ventricular tachycardias that require epicardial ablationin ischemic heart disease. J Cardiovasc Electrophysiol. 2012 ; 23 : 188-93.
 
9) Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia : a European multicenter study. Circ Arrhythm Electrophysiol. 2011 ; 4 : 653-9.
PubMed
10) Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemiccardiomyopathy compared with ischemic cardiomyopathy : results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014 ; 129 : 728-36.
PubMed
11) Tokuda M, Tedrow UB, Kojodjojo P, et al. Catheter ablation of ventricular tachycardia in nonischemic heart disease. Circ Arrhythm Electrophysiol. 2012 ; 5 : 992-1000.
PubMed
P.221 掲載の参考文献
1) Haissaguerre M, Jais P, Shah DC, et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1996 ; 7 : 1132-44.
PubMed
2) Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 ; 339 : 659-66.
PubMed
3) Haissaguerre M, Shah DC, Jais P, et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation. 2000 ; 102 : 2463-5.
 
4) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版). www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf
 
5) Mujovic N, Marinkovic M, Lenarczyk R, et al. Catheter ablation of atrial fibrillation : an overview for clinicians. Adv Ther. 2017 ; 34 : 1897-917.
PubMed
6) Jais P, Hocini M, Hsu LF, et al. Technique and results of linear ablation at the mitral isthmus. Circulation. 2004 ; 110 : 2996-3002.
PubMed
7) Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation : mapping of the electrophysiologic substrate. J Am Coll Cardiol. 2004 ; 43 : 2044-53.
PubMed
8) Nakagawa H, Scherlag BJ, Jackman WM, et al. Pathophysiologic basis of autonomic ganglionated plexus ablation in patients with atrial fibrillation. Heart Rhythm. 2009 ; 6 : S26-34.
PubMed
9) Yagishita A, Gimbel JR, DE Oliveira S, et al. Long-term outcome of left atrial voltage-guided substrate ablation during atrial fibrillation : a novel adjunctive ablation strategy. J Cardiovasc Electrophysiol. 2017 ; 28 : 147-55.
PubMed
10) Narayan SM, Krummen DE, Shivkumar K, et al. Treatment of atrial fibrillation by the ablation of localized sources : CONFIRM (Conventional Ablation for Atrial Fibrillation with or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol. 2012 ; 60 : 628-36.
 
11) Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation : a systematic review. Heart Rhythm. 2010 ; 7 : 835-46.
PubMed
12) Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation : the A4 study. Circulation. 2008 ; 118 : 2498-505.
PubMed
13) Inoue K, Murakawa Y, Nogami A, et al. Current status of catheter ablation of atrial fibrillation in Japan : Summary of the 4th survey of the Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). J Cardiol. 2016 ; 68 : 83-8.
PubMed
14) Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death : data from Swedish health registry. Eur Heart J. 2016 ; 37 : 2478-87.
PubMed
15) Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation : the CABANA randomized clinical trial. JAMA. 2019 ; 321 : 1261-74.
 
16) Gomez-Outes A, Lagunar-Ruiz J, Terleira-Fernandez AI, et al. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2016 ; 68 : 2508-21.
PubMed
17) Kalantarian S, Stern TA, Mansour M, et al. Cognitive impairment associated with atrial fibrillation. Ann Intern Med. 2013 ; 158 : 338-46.
PubMed
18) Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. 2011 : 22 : 839-45.
PubMed
19) Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008 ; 358 : 2667-77.
PubMed
20) Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (The CAMTAF Trial). Circ Arrhyth Electrophysiol. 2014 ; 7 : 31-8.
 
21) Narui R, Yamane T, Tokuda M, et al. Atrial fibrillation diagnosed by a medical checkup is associated with a poor outcome of catheter ablation. Heart Vessels. 2018 ; 33 : 770-6.
PubMed
P.229 掲載の参考文献
1) 杉山幸生, 宮下光太郎. 脳梗塞. 2 心原性脳塞栓症. In : 田中耕太郎, 高島修太郎, 編. 必携 脳卒中ハンドブック. 東京 : 診断と治療社 ; 2008. p.211-4.
 
2) Kernan WN, et al ; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 ; 45 : 2160-236.
PubMed
3) Toyoda K, et al ; SAMURAI Study Investigators. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan : the SAMURAI-NVAF study. Int J Stroke. 2015 ; 10 : 836-42.
 
4) Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 ; 37 : 2893-962.
PubMed
5) Seiffge DJ, Traenka C, Polymeris A, et al. Early start of DOAC after ischemic stroke : Risk of intracranial hemorrhage and recurrent events. Neurology. 2016 ; 87 : 1856-62.
 
6) 脳梗塞急性期. 1-5 開頭減圧療法. In : 日本脳卒中学会 脳卒中ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015. p.66.
 
7) Pillai A, Menon SK, Kumar S, et al. Decompressive hemicraniectomy in malignant middle cerebral artery infarction : an analysis of long-term outcome and factors in patient selection. J Neurosurg. 2007 ; 106 : 59-65.
PubMed
8) Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery : a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007 ; 6 : 215-22.
PubMed
9) 奥村謙, 目時典文, 萩井譲士. 心原性脳梗塞の疫学と重症度. 心電図. 2011 ; 31 : 292-6.
Medical*Online
10) 祢津智久, 細見直永, 松本昌泰, 他. 心房細動例におけるCHADS2スコアと重症度, 予後. In : 小林祥泰, 編. 脳卒中データバンク 2015. 東京 : 中山書店 ; 2015. p.60-1.
 
11) 坂田修治, 小林祥泰. 出血性脳梗塞 : 頻度, 重症度, 血栓溶解療法との関係. In : 小林祥泰, 編. 脳卒中データバンク 2015. 東京 : 中山書店 ; 2015. p.66-8.
 
P.235 掲載の参考文献
1) 奥村謙, 目時典文. 心原性脳塞栓のクリティカルケア-心房細動の管理の重要性- (1) 脳梗塞の重症度別にみた退院時の重症度. Clinician. 2007 ; 557 : 343.
 
2) 小谷英太郎, 新博次, 奥村謙, 他. 心房細動に対するワルファリン療法における日本人の至適INR-J-RHYTHM Registryからの報告-. 心電図. 2013 ; 33 : 25-31.
Medical*Online
3) Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation : observing outcomes associated with varying levels of INR control. Thromb Res. 2009 ; 124 : 37-41.
PubMed
4) Okumura K, Yamashita T, Harada M, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. -A multicenter study of its status and influential factors-. Circ J. 2011 ; 75 : 2087-94.
 
5) Sato H, Ishikawa K, Kitabatake A, et al ; Japan Atrial Fibrillation Stroke Trial (JAST) group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation. Japan Atrial Fibrillation Stroke Trial. Stroke. 2006 ; 37 : 447-51.
 
6) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 : 1139-51.
PubMed
7) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010 ; 363 : 1875-6.
 
8) Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 : 883-91.
PubMed
9) Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 ; 365 : 981-92.
PubMed
10) Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 ; 369 : 2093-104.
PubMed
11) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994 ; 154 : 1449-57.
PubMed
12) Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke. 2008 ; 39 : 1740-5.
PubMed
13) Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 ; 120 : 700-5.
PubMed
14) Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009 ; 151 : 297-305.
 
15) Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population : a modelling analysis based on a nationwide cohort study. Thrombo Haemost. 2012 ; 107 : 584-9.
 
16) Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 ; 369 : 1206-14.
PubMed
P.249 掲載の参考文献
1) Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016 ; 67 : e27-115.
 
2) 日本循環器学会. カテーテルアブレーションの適応と手技に関するガイドライン. www.j-circ.or.jp/guideline/pdf/JCS2012.okumura_h.pdf
 
3) Taguchi N, Yoshida N, Inden Y, et al. A simple algorithm for localizing accessory pathways in patients with Wolff-Parkinson-White syndrome using only the R/Sratio. J Arrhythmia. 2014 ; 30 : 439-43.
 
4) Lipscomb KJ, Zaidi AM, Fitzpatrick AP, et al. Slow pathway modification for atrioventricular node reentrant tachycardia : fast junctional tachycardia predicts adverse prognosis. Heart. 2001 ; 85 : 44-7.
PubMed
5) Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll Cardiol. 2013 ; 61 : 793-801.
PubMed
P.257 掲載の参考文献
1) Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol. 2005 ; 45 : 1259-65.
 
2) Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010 ; 7 : 865-9.
PubMed
3) El Kadri M, Yokokawa M, Labounty T, et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. Heart Rhythm. 2015 ; 12 : 706-13.
PubMed
4) Nogami A. Mapping and ablating ventricular premature contractions that trigger ventricular fibrillation : trigger elimination and substrate modification. J Cardiovasc Electrophysiol. 2015 ; 26 : 110-5.
PubMed
5) Lakkireddy D, Di Biase L, Ryschon K, et al. Radiofrequency ablation of premature ventricular ectopy improves the efficacy of cardiac resynchronization therapy in nonresponders. J Am Coll Cardiol. 2012 ; 60 : 1531-9.
PubMed
6) Ito S, Tada H, Naito S, et al. Development and validation of an ECG algorithm for identifying the optimal ablation site for idiopathic ventricular outflow tract tachycardia. J Cardiovasc Electrophysiol. 2003 ; 14 : 1280-6.
PubMed
7) Yamada T, Platonov M, Kay N, et al. Left ventricular outflow tract tachycardia with preferential conduction and multiple exits. Circ Arrhythm Electrophysiol. 2008 ; 1 : 140-2.
 
8) Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic vermicular tachycardia originating from the aortic sinus cusp. Electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol. 2002 ; 39 : 500-8.
 
9) Morady F, Kadish AH, DiCarlo L, et al. Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation. 1990 ; 82 : 2093-9.
PubMed
10) Santangeli P, Marchlinski FE, Zado ES, et al. Percutaneous epicardial ablation of ventricular arrhythmias arising from the left ventricular summit : outcomes and electrocardiogram correlates of success. Circ Arrhythm Electrophysiol. 2015 ; 8 : 337-43.
PubMed
P.273 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版). www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf
 
2) 野上昭彦, 小林義典, 里見和浩, 編. 心室頻拍のすべて. 東京 : 南江堂 ; 2016.
 
3) Marchlinski FE, Callans DJ, Gottlieb CD, et al. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation. 2000 ; 101 : 1288-96.
PubMed
4) Soejima K, Suzuki M, Maisel WH, et al. Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction : short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation. 2001 ; 104 : 664-9.
PubMed
5) Soejima K, Stevenson WG, Maisel WH, et al. Electrically unexcitable scar mapping based on pacing threshold for identification of the reentry circuit isthmus : feasibility for guiding ventricular tachycardia ablation. Circulation. 2002 ; 106 : 1678-83.
PubMed
6) Arenal A, del Castillo S, Gonzalez-Torrecilla E, et al. Tachycardia-related channel in the scar tissue in patients with sustained monomorphic ventricular tachycardias : influence of the voltage scar definition. Circulation. 2004 ; 110 : 2568-74.
PubMed
7) Arenal A, Glez-Torrecilla E, Ortiz M, et al. Ablation of electrograms with an isolated, delayed component as treatment of unmappable monomorphic ventricular tachycardias in patients with structural heart disease. J Am Coll Cardiol. 2003 ; 41 : 81-92.
 
8) Vergara P, Trevisi N, Ricco A, et al. Late potentials abolition as an additional technique for reduction of arrhythmia recurrence in scar related ventricular tachycardia ablation. J Cardiovasc Electrophysiol. 2012 ; 23 : 621-7.
PubMed
9) Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2012 ; 60 : 132-41.
PubMed
10) Jais P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities : a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. 2012 ; 125 : 2184-96.
PubMed
11) Berruezo A, Fernandez-Armenta J, Mont L, et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol. 2012 ; 5 : 111-21.
PubMed
12) Tung R, Mathuria NS, Nagel R, et al. Impact of local ablation on interconnected channels within ventricular scar : mechanistic implications for substrate modification. Circ Arrhythm Electrophysiol. 2013 ; 6 : 1131-8.
PubMed
13) Tilz RR, Makimoto H, Lin T, et al. Electrical isolation of a substrate after myocardial infarction : a novel ablation strategy for unmappable ventricular tachycardias-feasibility and clinical outcome. Europace. 2014 ; 16 : 1040-52.
PubMed
14) Tzou WS, Frankel DS, Hegeman T, et al. Core isolation of critical arrhythmia elements for treatment of multiple scar-based ventricular tachycardias. Circ Arrhythm Electrophysiol. 2015 ; 8 : 353-61.
PubMed
P.284 掲載の参考文献
1) Haissaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003 ; 108 : 925-8.
PubMed
2) Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011 ; 123 : 1270-9.
PubMed
3) Sacher F, Jesel L, Jais P, et al. Insight into the mechanism of Brugada syndrome : epicardial substrate and modification during Ajimaline testing. Heart Rhythm. 2014 ; 11 : 732-4.
PubMed
4) Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol. 2015 ; 8 : 1373-81.
PubMed
5) Zhang P, Tung R, Zhang Z, et al. Characterization of the epicardial substrate for catheter ablation of Brugada syndrome. Heart Rhythm. 2016 ; 13 : 2151-8.
PubMed
6) Talib AK, Takagi M, Shimane A, et al. Efficacy of endocardial ablation of drug-resistant ventricular fibrillation in Brugada syndrome : long-term outcome. Circ Arrhythm Electrophysiol. 2018 ; 11 : e005631.
PubMed
7) Nademanee K, Raju H, de Noronha SV, et al. Fibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome. J Am Coll Cardiol. 2015 ; 66 : 1976-86.
PubMed
8) Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de pointes : a new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994 ; 89 : 206-15.
PubMed
9) Kaneshiro T, Nogami N, Kato Y, et al. Effects of catheter ablation targeting the trigger beats in inherited catecholaminergic polymorphic ventricular tachycardia. JACC CEP. 2017 ; Sep ; 3 (9) : Doi : 10.1016/j.jacep.2017.04.017
 
10) Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002 ; 106 : 962-7.
PubMed
11) Nogami A, Sugiyasu A, Kubota S, et al. Mapping and ablation of idiopathic ventricular fibrillation from Purkinje system. Heart Rhythm. 2005 ; 2 : 646-9.
PubMed
P.291 掲載の参考文献
1) 清水渉. 3) 遺伝性不整脈. 7-4 循環器疾患と遺伝子異常. 7. 循環器系の疾患. In : 矢崎義雄, 総編集. 内科学. 第11版. 東京 : 朝倉書店 ; 2017. p.423-7.
 
2) 清水渉. 4) 突然死. 7-6 不整脈. 7. 循環器系の疾患. 矢崎義雄, 総編集. 内科学. 第11版. 東京 : 朝倉書店 ; 2017. p.508-10.
 
3) Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009 ; 120 : 1761-7.
PubMed
4) Shimizu W, Makimoto H, Yamagata K, et al. Association of genetic and clinical aspects of congenital long QT syndrome with life-threatening arrhythmias in Japanese patients. JAMA Cardiol. 2019 ; 4 : 246-54.
PubMed
5) Mizusawa Y, Horie M, Wilde AA. Genetic and clinical advances in congenital long QT syndrome. Circ J. 2014 ; 78 : 2827-33.
PubMed
6) Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart rhythm. 2013 ; 10 : 1932-63.
PubMed
7) Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol. 2003 ; 41 : 633-42.
PubMed
8) Shimizu W, Noda T, Takaki H, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004 ; 1 : 276-83.
PubMed
9) Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007 ; 115 : 2481-9.
PubMed
10) Shimizu W, Moss AJ, Wilde AA, et al. Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol. 2009 ; 54 : 2052-62.
PubMed
11) Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome : an international multicenter study. Circulation. 2016 ; 134 : 872-82.
PubMed
12) 遺伝性不整脈の診療に関するガイドライン (2017年改訂版). www.j-circ.or.jp/guideline/PDF/JCS2017_aonuma_h.pdf
 

Ch.3 不整脈治療の実践

P.307 掲載の参考文献
1) Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7 : adult advanced cardiovascular life support : 2015 American Heart Association Guidelines update for cardiopulmonary resuscitation and emergency cardiovascular Care. Circulation. 2015 ; 132 (suppl 2) : S444-64.
 
2) 日本蘇生協議会, 監修. JRC蘇生ガイドライン 2015. 東京 : 医学書院 ; 2016.
 
3) Zipes DP. Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation. 1990 ; 82 : 1095-105.
PubMed
4) Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000 ; 102 : 742-7.
PubMed
5) Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : Executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 ; 138 : e210-71.
 
6) Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Eur Heart J. 2015 ; 36 : 2793-867.
 
7) 日本循環器学会. 不整脈薬物治療に関するガイドライン (2009年改訂版). www.j-circ.or.jp/guideline/pdf/JSC2009_kodama_h.pdf
 
8) Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999 ; 341 : 871-8.
PubMed
9) Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002 ; 346 : 884-90.
PubMed
10) Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016 ; 374 : 1711-22.
 
11) Kudenchuk PJ, Leroux BG, Daya M, et al ; Resuscitation Outcomes consortium investigators. Antiarrhythmic drugs for nonshockable-turned-shockable out-of-hospital cardiac arrest : the ALPS study (amiodarone, lidocaine, or placebo). Circulation. 2017 ; 136 : 2119-31.
PubMed
12) Kato T, Ogawa S, Yamaguchi I, et al. Efficacy and safety of intravenous amiodarone infusion in Japanese patients with hemodynamically compromised ventricular tachycardia of ventricular fibrillation. J Arrhythmia. 2007 ; 23 : 131-9.
 
13) Yusu S, Ikeda T, Mera H, et al. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. Circ J. 2009 ; 73 : 2021-8.
PubMed
14) Shiga T, Tanaka K, Kato R, et al. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia. Resuscitation. 2010 ; 81 : 47-52.
 
15) Amino M, Inokuchi S, Nagao K, et al. Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24-hour survival in cardiopulmonary arrest patients : The SOS-KANTO 2012 Study. J Cardiovasc Pharmacol. 2015 ; 66 : 600-9.
 
16) Ortiz M, Martin A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia : the PROCAMIO study. Eur Heart J. 2017 ; 38 : 1329-35.
PubMed
17) Miwa Y, Ikeda T, Mera H, et al. Effects of landiolol, an ultra-short-acting β1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J. 2010 ; 74 : 856-63.
 
18) Ikeda T, Shiga T, Shimizu W, et al. Efficacy and safety of the ultra-short-acting β1-selective blocker landiolol in patients with recurrent hemodynamically unstable ventricular tachyarrhymias : Outcomes of J-Land II Study. Circ J. 2019 May. doi : 10.1253/circj.CJ-18-1361. [ Epub ahead of print]
 
P.320 掲載の参考文献
1) Zipes DP. Preexcitation Syndrome. In : Braunwald E, ed. Heart disease. 5th ed. Philadelphia : Saunders ; 1997. p.667-75.
 
2) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版). www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf
 
3) Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation : executive summary. J Arrhythm. 2017 ; 33 : 369-409.
 

書評

最近チェックした商品履歴

Loading...